enVVeno Medical (NVNO) Net Income towards Common Stockholders (2017 - 2026)

enVVeno Medical's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 14.68% year-over-year to -$4.0 million in Q1 2026; TTM through Mar 2026 was -$19.5 million, a 15.18% increase from a year earlier, with the FY2025 full-year figure at -$20.6 million, up 13.51% from the prior year.
• Net Income towards Common Stockholders declined to -$4.0 million in Q1 2026 per NVNO's latest filing, from -$3.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$3.9 million in Q4 2025 and bottomed at -$7.7 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$6.1 million (2024), against an average of -$5.9 million.
• Across the five-year window, Net Income towards Common Stockholders sank 155.35% in 2022 and jumped 42.47% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$6.7 million in 2022, then slipped by 14.24% to -$7.7 million in 2023, then rose by 10.8% to -$6.8 million in 2024, then jumped by 42.47% to -$3.9 million in 2025, then declined by 2.64% to -$4.0 million in 2026.
• Per Business Quant, the three latest NVNO Net Income towards Common Stockholders figures stand at -$4.0 million (Q1 2026), -$3.9 million (Q4 2025), and -$4.7 million (Q3 2025).